Skip to content

US · YDES · BIOTECHNOLOGY

YD Bio Limited Ordinary Shares (YDES) intrinsic value and stock valuation

$4.83as of 2026-11-21 · Mkt cap 159.37M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

YD Bio Limited Ordinary Shares DCF and intrinsic value

InvestorsCraft values YDES with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from YDES’s statements →

YD Bio Limited Ordinary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Taipei, TP 115001 ydesgroup.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$600K
20202025
Net income
-$-8.31M
20202025
Free cash flow
-$-8.04M
20202025
Total equity
-$-2.86M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$600K$510K$350K$0.00$0.00
Operating income-$-5.27M-$-1.46M-$-10K-$-2.32M-$-1.72M
Net income-$-8.31M-$-1.41M$10K$3.79M$8.7M
EPSd-$-124.55K-$-339.76K$142.65$408K$594.7K
Operating cash flow-$-6.6M-$-1.84M-$-60K-$-3.02M-$-690K
Capital expenditure-$-1.44M-$-2.91M-$0.00$0.00-$0.00
Free cash flow-$-8.04M-$-4.75M-$-60K-$-3.02M-$-690K
Total assets$13.8M$6.86M$320K$17.9M$118.1M
Total debt$10K$20K$50K$0.00$0.00
Net debt-$-6M-$-3.11M-$-40K-$-10K-$-10K
Total equity-$-2.86M$6.59M$20K$11.2M$109M
Cash and short-term investments$6.01M$3.13M$90K$10K$10K
Income statement
20252024202320222021
Revenue$600K$510K$350K$0.00$0.00
Cost of revenue$640K$360K$200K$0.00$0.00
Gross profit-$-40K$160K$150K$0.00$0.00
Research and development expenses$1.6M$490K$0.00$0.00$0.00
Selling, general and administrative expenses$3.63M$1.13M$160K$2.32M$1.72M
Other expenses$0.00-$0.00$0.00$0.00$0.00
Operating expenses$5.23M$1.62M$160K$2.32M$1.72M
Cost and expenses$5.87M$1.97M$360K$2.32M$1.72M
Interest income$80K$10K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$210K$100K$0.00$0.00$0.00
Ebitda-$-8.1M-$-1.28M$20K$3.79M$8.7M
Operating income-$-5.27M-$-1.46M-$-10K-$-2.32M-$-1.72M
Total other income/expenses, net-$-3.04M$80K$30K$6.11M$10.4M
Income before tax-$-8.31M-$-1.39M$20K$3.79M$8.7M
Income tax expense-$0.00$30K$0.00$0.00$0.00
Net income-$-8.31M-$-1.41M$10K$3.79M$8.7M
Weighted average shares outstanding$66.7M$4.15M$70.1M$9.29M$14.6M
Weighted average diluted shares outstanding$66.7M$4.15M$70.1M$9.29M$14.6M
Balance sheet
20252024202320222021
Cash and short-term investments$6.01M$3.13M$90K$10K$10K
Net receivables$710K$260K$100K$20K$0.00
Inventory$1.88M$40K$70K$0.00$0.00
Total current assets$9.67M$3.47M$270K$200K$130K
Property, plant and equipment, net$70K$90K$10K$0.00$0.00
Goodwill and intangible assets$2.61M$2.68M$0.00$0.00$0.00
Long-term investments$0.00$10.5M$10K$17.7M$117.9M
Total non-current assets$4.11M$3.4M$50K$17.7M$117.9M
Total assets$13.8M$6.86M$320K$17.9M$118.1M
Accounts payable$410K$30K$20K$0.00$0.00
Short-term debt$10K$20K$50K$0.00$0.00
Deferred revenue$30K$0.00$0.00$0.00$0.00
Total current liabilities$1.64M$260K$300K$5.55M$2M
Long-term debt$0.00$10K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15M$10K$2.2M$1.18M$7.11M
Capital lease obligations$10K$20K$10K$0.00$0.00
Total liabilities$16.6M$270K$300K$6.74M$9.11M
Common stock$10K$140K$110K$17.7M$115M
Retained earnings-$-10.24M-$-1.93M-$-520K-$-6.53M-$-6.52M
Accumulated other comprehensive income (loss)$210K$50K$50K$0.00$0.00
Total equity-$-2.86M$6.59M$20K$11.2M$109M
Total investments$0.00$10.5M$10K$17.7M$117.9M
Total debt$10K$20K$50K$0.00$0.00
Net debt-$-6M-$-3.11M-$-40K-$-10K-$-10K
Cash flow statement
20252024202320222021
Net income-$-8.31M-$-1.41M$10K$3.79M$8.7M
Depreciation and amortization$210K$100K$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-1.69M-$-570K-$-130K-$-700K$630K
Accounts receivable-$-360K-$-10K-$-60K$0.00$0.00
Inventory-$-1.84M$30K-$-30K$0.00$0.00
Accounts payable$390K$10K$10K-$-530K$530K
Net cash provided by operating activities-$-6.6M-$-1.84M-$-60K-$-3.02M-$-690K
Investments in property, plant and equipment-$-1.44M-$-70K-$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.44M-$-2.9M-$0.00$100.4M-$-1.15M
Common stock issued$10.7M$7.86M$50K$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-101.55M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.9M$7.73M$110K-$-97.34M$1.15M
Net change in cash$2.88M$3.05M$60K$10K-$-690K
Cash at end of period$6.01M$3.13M$90K$10K$10K
Operating cash flow-$-6.6M-$-1.84M-$-60K-$-3.02M-$-690K
Capital expenditure-$-1.44M-$-2.91M-$0.00$0.00-$0.00
Free cash flow-$-8.04M-$-4.75M-$-60K-$-3.02M-$-690K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About YD Bio Limited Ordinary Shares

        Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

        CEO
        Ethan Shen
        Employees
        15
        Beta
        -0.12

        Explore

        Frequently asked questions

        What is the intrinsic value of YD Bio Limited Ordinary Shares (YDES)?

        InvestorsCraft does not currently publish an intrinsic value for YDES. How the IC value is calculated.

        Is YDES undervalued?

        InvestorsCraft does not publish an undervaluation signal for YDES at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.